Analysts Just Published A Bright New Outlook For 3SBio Inc.'s (HKG:1530)
May 26
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedMay 28, 2025
DataAggregated Company Financials
Companies52
- 7D2.8%
- 3M30.3%
- 1Y74.9%
- YTDn/a
Over the last 7 days, the Biotech industry has risen 4.8%, driven by gains from Innovent Biologics of 7.7%. Meanwhile, Sichuan Kelun-Biotech Biopharmaceutical actually underperformed within the industry, shrinking 5.5% in the last week. This means that the industry has gained 69% over the past year. Earnings are forecast to grow by 43% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 28 May 2025 | HK$614.7b | HK$62.1b | -HK$11,728,537,749.57 | 31.4x | -52.4x | 9.9x |
| Fri, 25 Apr 2025 | HK$592.6b | HK$60.3b | -HK$12,142,775,488.57 | 31x | -48.8x | 9.8x |
| Sun, 23 Mar 2025 | HK$462.3b | HK$52.9b | -HK$16,611,212,337.88 | 22.3x | -27.8x | 8.7x |
| Tue, 18 Feb 2025 | HK$387.6b | HK$52.1b | -HK$17,339,275,607.70 | 14.2x | -22.4x | 7.4x |
| Thu, 16 Jan 2025 | HK$345.4b | HK$51.8b | -HK$17,187,867,166.23 | 12x | -20.1x | 6.7x |
| Sat, 14 Dec 2024 | HK$396.2b | HK$52.0b | -HK$17,296,920,183.53 | 11.2x | -22.9x | 7.6x |
| Mon, 11 Nov 2024 | HK$403.2b | HK$52.5b | -HK$17,637,137,036.48 | 11.6x | -22.9x | 7.7x |
| Wed, 09 Oct 2024 | HK$429.0b | HK$52.8b | -HK$18,074,318,821.05 | 12.6x | -23.7x | 8.1x |
| Fri, 06 Sep 2024 | HK$338.4b | HK$52.6b | -HK$19,559,560,948.74 | 11.2x | -17.3x | 6.4x |
| Sun, 04 Aug 2024 | HK$322.2b | HK$50.2b | -HK$19,725,019,237.43 | 11.5x | -16.3x | 6.4x |
| Tue, 02 Jul 2024 | HK$327.6b | HK$49.6b | -HK$19,444,681,872.35 | 12.1x | -16.9x | 6.6x |
| Thu, 30 May 2024 | HK$327.6b | HK$49.8b | -HK$19,496,944,310.65 | 10.7x | -16.8x | 6.6x |
| Sat, 27 Apr 2024 | HK$356.8b | HK$49.5b | -HK$19,466,746,223.62 | 11.9x | -18.3x | 7.2x |
| Mon, 25 Mar 2024 | HK$345.6b | HK$49.7b | -HK$19,699,938,439.12 | 14.1x | -17.5x | 7x |
| Wed, 21 Feb 2024 | HK$334.9b | HK$46.8b | -HK$20,169,434,820.59 | 16.7x | -16.6x | 7.2x |
| Fri, 19 Jan 2024 | HK$356.0b | HK$46.8b | -HK$20,179,533,390.00 | 17.3x | -17.6x | 7.6x |
| Sun, 17 Dec 2023 | HK$406.1b | HK$47.1b | -HK$20,339,000,495.00 | 17.9x | -20x | 8.6x |
| Tue, 14 Nov 2023 | HK$409.2b | HK$45.2b | -HK$18,917,442,048.00 | 13.6x | -21.6x | 9.1x |
| Thu, 12 Oct 2023 | HK$392.6b | HK$44.9b | -HK$19,102,915,645.00 | 13.9x | -20.6x | 8.7x |
| Sat, 09 Sep 2023 | HK$402.2b | HK$44.8b | -HK$18,854,481,037.00 | 15.4x | -21.3x | 9x |
| Mon, 07 Aug 2023 | HK$398.2b | HK$35.6b | -HK$23,393,254,800.00 | 22.3x | -17x | 11.2x |
| Wed, 05 Jul 2023 | HK$412.9b | HK$35.4b | -HK$23,279,014,142.00 | 25.5x | -17.7x | 11.7x |
| Fri, 02 Jun 2023 | HK$408.8b | HK$35.8b | -HK$23,623,817,169.00 | 27.5x | -17.3x | 11.4x |
| Sun, 30 Apr 2023 | HK$444.9b | HK$37.1b | -HK$23,353,957,554.00 | 17.8x | -19.1x | 12x |
| Tue, 28 Mar 2023 | HK$434.1b | HK$35.1b | -HK$35,011,853,187.00 | 23.5x | -12.4x | 12.4x |
| Thu, 23 Feb 2023 | HK$415.1b | HK$34.5b | -HK$34,789,181,444.00 | 33.3x | -11.9x | 12x |
| Sat, 21 Jan 2023 | HK$452.1b | HK$34.9b | -HK$35,261,292,869.00 | 29.8x | -12.8x | 13x |
| Mon, 19 Dec 2022 | HK$394.6b | HK$33.6b | -HK$33,868,975,451.00 | 24.3x | -11.7x | 11.8x |
| Wed, 16 Nov 2022 | HK$379.5b | HK$33.4b | -HK$33,666,828,900.00 | 17.8x | -11.3x | 11.4x |
| Fri, 14 Oct 2022 | HK$277.4b | HK$33.8b | -HK$32,282,437,029.00 | 15.7x | -8.6x | 8.2x |
| Sun, 11 Sep 2022 | HK$356.2b | HK$34.5b | -HK$33,767,111,427.00 | 16.9x | -10.5x | 10.3x |
| Tue, 09 Aug 2022 | HK$338.4b | HK$32.8b | -HK$46,282,522,083.00 | 12x | -7.3x | 10.3x |
| Thu, 07 Jul 2022 | HK$382.6b | HK$33.0b | -HK$46,512,140,844.00 | 15.2x | -8.2x | 11.6x |
| Sat, 04 Jun 2022 | HK$326.3b | HK$34.2b | -HK$46,188,313,755.00 | 13.2x | -7.1x | 9.5x |
Price to Earnings Ratio
-7.1x
Current Industry PE
- Investors are relatively neutral on the Hong Kong Biotechnology industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 9.1x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Revenues for these companies have grown 22% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Hong Kong Biotech compare with similar industries?
| HK Market | 0.04% | |
| Healthcare | 3.13% | |
| Biotech | 2.76% | |
| Biotech | 2.76% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1801 Innovent Biologics | HK$60.20 | 7.7% +HK$7.1b | 68.2% | PS9.7x | |
| 1877 Shanghai Junshi Biosciences | HK$18.18 | 7.3% +HK$1.2b | 63.8% | PS7.9x | |
| 1541 ImmuneOnco Biopharmaceuticals (Shanghai) | HK$10.84 | 32.2% +HK$1.1b | -25.1% | PS50.9x | |
| 9606 Duality Biotherapeutics | HK$207.00 | 6.2% +HK$1.1b | n/a | PS8.6x | |
| 2487 Cutia Therapeutics | HK$10.26 | 37.5% +HK$892.0m | 40.5% | PS10.7x |
